Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2012, Article ID 513702, 9 pages
http://dx.doi.org/10.1155/2012/513702
Review Article

Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies

1Cancer Biology PhD Program, University of South Florida, Tampa, FL 33620, USA
2Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
3Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA

Received 16 November 2011; Revised 12 May 2012; Accepted 18 June 2012

Academic Editor: Anna Marina Liberati

Copyright © 2012 Jessica M. McDaniel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. G. Iyer, J. Languillon, K. Ramanujam et al., “WHO co-ordinated short-term double-blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients,” Bulletin of the World Health Organization, vol. 45, no. 6, pp. 719–732, 1971. View at Google Scholar · View at Scopus
  2. J. Sheskin, “The treatment of lepra reaction in lepromatous leprosy. Fifteen years' experience with thalidomide,” International Journal of Dermatology, vol. 19, no. 6, pp. 318–322, 1980. View at Google Scholar · View at Scopus
  3. O. Gutierrez-Rodriguez, “Thalidomide: a promising new treatment for rheumatoid arthritis,” Arthritis and Rheumatism, vol. 27, no. 10, pp. 1118–1121, 1984. View at Google Scholar · View at Scopus
  4. E. Atra and E. I. Sato, “Treatment of the cutaneous lesions of systemic lupus erythematosus with thalidomide,” Clinical and Experimental Rheumatology, vol. 11, no. 5, pp. 487–493, 1993. View at Google Scholar · View at Scopus
  5. M. H. Hamza, “Treatment of Behcet's disease with thalidomide,” Clinical Rheumatology, vol. 5, no. 3, pp. 365–371, 1986. View at Google Scholar · View at Scopus
  6. G. W. Muller, L. G. Corral, M. G. Shire et al., “Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity,” Journal of Medicinal Chemistry, vol. 39, no. 17, pp. 3238–3240, 1996. View at Publisher · View at Google Scholar · View at Scopus
  7. V. Kotla, S. Goel, S. Nischal et al., “Mechanism of action of lenalidomide in hematological malignancies,” Journal of Hematology and Oncology, vol. 2, article 36, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. V. Saloura and P. D. Grivas, “Lenalidomide: a synthetic compound with an evolving role in cancer management,” Hematology, vol. 15, no. 5, pp. 318–331, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Carballido, M. Veliz, R. Komrokji, and J. Pinilla-Ibarz, “Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia,” Cancer Control, vol. 19, no. 1, pp. 54–67, 2012. View at Google Scholar · View at Scopus
  10. G. P. Dunn, A. T. Bruce, H. Ikeda, L. J. Old, and R. D. Schreiber, “Cancer immunoediting: from immunosurveillance to tumor escape,” Nature Immunology, vol. 3, no. 11, pp. 991–998, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. V. Shankaran, H. Ikeda, A. T. Bruce et al., “IFNγ, and lymphocytes prevent primary tumour development and shape tumour immunogenicity,” Nature, vol. 410, no. 6832, pp. 1107–1111, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. P. A. J. Haslett, L. G. Corral, M. Albert, and G. Kaplan, “Thalidomide costimulates primary human t lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset,” Journal of Experimental Medicine, vol. 187, no. 11, pp. 1885–1892, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. A. List, S. Kurtin, D. J. Roe et al., “Efficacy of lenalidomide in myelodysplastic syndromes,” The New England Journal of Medicine, vol. 352, no. 6, pp. 549–557, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. P. S. Linsley, J. L. Greene, W. Brady, J. Bajorath, J. A. Ledbetter, and R. Peach, “Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors,” Immunity, vol. 1, no. 9, pp. 793–801, 1994. View at Google Scholar · View at Scopus
  15. P. A. Bretscher, “A two-step, two-signal model for the primary activation of precursor helper T cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 1, pp. 185–190, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. J. A. Keene and J. Forman, “Helper activity is required for the in vivo generation of cytotoxic T lymphocytes,” Journal of Experimental Medicine, vol. 155, no. 3, pp. 768–782, 1982. View at Google Scholar · View at Scopus
  17. T. Mustelin and K. Taskén, “Positive and negative regulation of T-cell activation through kinases and phosphatases,” Biochemical Journal, vol. 371, part 1, pp. 15–27, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. M. A. Williams, A. J. Tyznik, and M. J. Bevan, “Interleukin-2 signals during priming are required for secondary expansion of CD8+ memory T cells,” Nature, vol. 441, no. 7095, pp. 890–893, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. T. Nakayama and M. Yamashita, “The TCR-mediated signaling pathways that control the direction of helper T cell differentiation,” Seminars in Immunology, vol. 22, no. 5, pp. 303–309, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. R. LeBlanc, T. Hideshima, L. P. Catley et al., “Immunomodulatory drug costimulates T cells via the B7-CD28 pathway,” Blood, vol. 103, no. 5, pp. 1787–1790, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. T. Hayashi, T. Hideshima, M. Akiyama et al., “Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application,” British Journal of Haematology, vol. 128, no. 2, pp. 192–203, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. F. Payvandi, L. Wu, S. D. Naziruddin et al., “Immunomodulatory drugs (IMiDs) increase the production of IL-2 from stimulated T cells by increasing PKC-θ activation and enhancing the DNA-binding activity of AP-1 but not NF-κB, OCT-1, or NF-AT,” Journal of Interferon and Cytokine Research, vol. 25, no. 10, pp. 604–616, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. P. H. Schafer, A. K. Gandhi, M. A. Loveland et al., “Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs,” Journal of Pharmacology and Experimental Therapeutics, vol. 305, no. 3, pp. 1222–1232, 2003. View at Publisher · View at Google Scholar · View at Scopus
  24. G. Görgün, E. Calabrese, E. Soydan et al., “Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma,” Blood, vol. 116, no. 17, pp. 3227–3237, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. J. Smyth, D. I. Godfrey, and J. A. Trapani, “A fresh look at tumor immunosurveillance and immunotherapy,” Nature Immunology, vol. 2, no. 4, pp. 293–299, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Galustian, B. Meyer, M. C. Labarthe et al., “The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells,” Cancer Immunology, Immunotherapy, vol. 58, no. 7, pp. 1033–1045, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. K. Giannopoulos, M. Schmitt, P. Własiuk et al., “The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide,” Leukemia, vol. 22, no. 1, pp. 222–224, 2008. View at Publisher · View at Google Scholar · View at Scopus
  28. J. M. McDaniel, J. X. Zou, W. Fulp, D.-T. Chen, A. F. List, and P. K. Epling-Burnette, “Reversal of T-cell tolerance in myelodysplastic syndrome through lenalidomide immune modulation,” Leukemia, vol. 26, no. 6, pp. 1425–1429, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Noonan, L. Rudraraju, A. Ferguson et al., “Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses,” Clinical Cancer Research, vol. 18, no. 5, pp. 1426–1434, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Scrivener, R. V. Goddard, E. R. Kaminski, and A. G. Prentice, “Abnormal T-cell function in B-cell chronic lymphocytic leukaemia,” Leukemia and Lymphoma, vol. 44, no. 3, pp. 383–389, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Kiaii, A. Choudhury, F. Mozaffari, E. Kimby, A. Österborg, and H. Mellstedt, “Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease,” Medical Oncology, vol. 22, no. 3, pp. 291–302, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. A. G. Ramsay, A. J. Clear, and R. Fatah, “Multiple inhibitory ligands induce impaired T cell immunological synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide,” Blood. In press.
  33. B. N. Lee, H. Gao, E. N. Cohen et al., “Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia,” Cancer, vol. 117, no. 17, pp. 3999–4008, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Neuber, I. Herth, C. Tolliver et al., “Lenalidomide enhances antigen-specific activity and decreases CD45RA expression of T cells from patients with multiple myeloma,” The Journal of Immunology, vol. 187, no. 2, pp. 1047–1056, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Ito, H. Ando, T. Suzuki et al., “Identification of a primary target of thalidomide teratogenicity,” Science, vol. 327, no. 5971, pp. 1345–1350, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. X. Zhu, E. Braggio, C.-X. Shi et al., “Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide,” Blood, vol. 118, no. 18, pp. 4771–4779, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. S. Ren, C. Xu, Z. Cui et al., “Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer,” Journal of Molecular Medicine. In press.
  38. S. Wei, X. Chen, K. McGraw et al., “Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion,” Oncogene. In press.
  39. F. T. Awan, A. J. Johnson, R. Lapalombella et al., “Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia,” Leukemia and Lymphoma, vol. 51, no. 1, pp. 27–38, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Chanan-Khan, K. C. Miller, L. Musial et al., “Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study,” Journal of Clinical Oncology, vol. 24, no. 34, pp. 5343–5349, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. C. I. Chen, P. L. Bergsagel, H. Paul et al., “Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 29, no. 9, pp. 1175–1181, 2011. View at Publisher · View at Google Scholar · View at Scopus
  42. A. Ferrajoli, B. N. Lee, E. J. Schlette et al., “Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia,” Blood, vol. 111, no. 11, pp. 5291–5297, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Chanan-Khan and C. W. Porter, “Immunomodulating drugs for chronic lymphocytic leukaemia,” The Lancet Oncology, vol. 7, no. 6, pp. 480–488, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. A. G. Ramsay, A. J. Johnson, A. M. Lee et al., “Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug,” The Journal of Clinical Investigation, vol. 118, no. 7, pp. 2427–2437, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. G. Gorgun, A. G. Ramsay, T. A. W. Holderried et al., “Eμ- TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 15, pp. 6250–6255, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. A. G. Ramsay, A. J. Clear, R. Fatah, and J. G. Gribben, “Lenalidomide repairs suppressed T cell immunological synapse formation in follicular lymphoma,” Blood, vol. 112, 2008, Abstract no. 885. View at Google Scholar
  47. A. A. Chanan-Khan, K. Chitta, N. Ersing et al., “Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response,” British Journal of Haematology, vol. 155, no. 4, pp. 457–467, 2011. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Chanan-Khan, K. C. Miller, D. Lawrence et al., “Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response,” Cancer, vol. 117, no. 10, pp. 2127–2135, 2011. View at Publisher · View at Google Scholar · View at Scopus
  49. M. V. Dhodapkar, M. D. Geller, D. H. Chang et al., “A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma,” Journal of Experimental Medicine, vol. 197, no. 12, pp. 1667–1676, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. R. T. Perri, M. M. Oken, and N. E. Kay, “Enhanced T cell suppression is directed toward sensitive circulating B cells in multiple myeloma,” Journal of Laboratory and Clinical Medicine, vol. 99, no. 4, pp. 512–519, 1982. View at Google Scholar · View at Scopus
  51. R. A. Kyle and S. V. Rajkumar, “Drug therapy: multiple myeloma,” The New England Journal of Medicine, vol. 351, no. 18, pp. 1860–1921, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. I. Breitkreutz, M. S. Raab, S. Vallet et al., “Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma,” Leukemia, vol. 22, no. 10, pp. 1925–1932, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. H. Geitz, S. Handt, and K. Zwingenberger, “Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade,” Immunopharmacology, vol. 31, no. 2-3, pp. 213–221, 1996. View at Publisher · View at Google Scholar · View at Scopus
  54. A. Lichtenstein, Y. Tu, C. Fady, R. Vescio, and J. Berenson, “Interleukin-6 inhibits apoptosis of malignant plasma cells,” Cellular Immunology, vol. 162, no. 2, pp. 248–255, 1995. View at Publisher · View at Google Scholar · View at Scopus
  55. R. D. Brown, B. Pope, A. Murray et al., “Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-β1 and interleukin-10,” Blood, vol. 98, no. 10, pp. 2992–2998, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Ratta, F. Fagnoni, A. Curti et al., “Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6,” Blood, vol. 100, no. 1, pp. 230–237, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. O. Christensen, A. Lupu, S. Schmidt et al., “Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24,” Journal of Immunotherapy, vol. 32, no. 6, pp. 613–621, 2009. View at Publisher · View at Google Scholar · View at Scopus
  58. T. Barlozzari, C. W. Reynolds, and R. B. Herberman, “In vivo role of natural killer cells: involvement of large granular lymphocytes in the clearance of tumor cells in anti-asialo GM1-treated rats,” The Journal of Immunology, vol. 131, no. 2, pp. 1024–1027, 1983. View at Google Scholar · View at Scopus
  59. V. C. Huber, J. M. Lynch, D. J. Bucher, J. Le, and D. W. Metzger, “Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections,” The Journal of Immunology, vol. 166, no. 12, pp. 7381–7388, 2001. View at Google Scholar · View at Scopus
  60. L. E. Wai, J. A. Garcia, O. M. Martinez, and S. M. Krams, “Distinct roles for the NK cell-activating receptors in mediating interactions with dendritic cells and tumor cells,” The Journal of Immunology, vol. 186, no. 1, pp. 222–229, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. F. E. Davies, N. Raje, T. Hideshima et al., “Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma,” Blood, vol. 98, no. 1, pp. 210–216, 2001. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Zhu, L. G. Corral, Y. W. Fleming, and B. Stein, “Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation,” Cancer Immunology, Immunotherapy, vol. 57, no. 12, pp. 1849–1859, 2008. View at Publisher · View at Google Scholar · View at Scopus
  63. A. K. Hsu, H. Quach, T. Tai et al., “The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy,” Blood, vol. 117, no. 5, pp. 1605–1613, 2011. View at Publisher · View at Google Scholar · View at Scopus
  64. E. Carbone, P. Neri, M. Mesuraca et al., “HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells,” Blood, vol. 105, no. 1, pp. 251–258, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. L. Wu, A. Parton, L. Lu, M. Adams, P. Schafer, and J. B. Bartlett, “Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers,” Cancer Immunology, Immunotherapy, vol. 60, no. 1, pp. 61–73, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. D. M. Benson Jr., C. E. Bakan, S. Zhang et al., “IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect,” Blood, vol. 118, no. 24, pp. 6387–6391, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. M. J. Butte, M. E. Keir, T. B. Phamduy, A. H. Sharpe, and G. J. Freeman, “Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses,” Immunity, vol. 27, no. 1, pp. 111–122, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, “PD-1 and its ligands in tolerance and immunity,” Annual Review of Immunology, vol. 26, pp. 677–704, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. D. M. Benson, C. E. Bakan, A. Mishra et al., “The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody,” Blood, vol. 116, no. 13, pp. 2286–2294, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Wu, M. Adams, T. Carter et al., “Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells,” Clinical Cancer Research, vol. 14, no. 14, pp. 4650–4657, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. E. Vivier, E. Tomasello, M. Baratin, T. Walzer, and S. Ugolini, “Functions of natural killer cells,” Nature Immunology, vol. 9, no. 5, pp. 503–510, 2008. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Kaufmann, M. Raderer, S. Wöhrer et al., “Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma,” Blood, vol. 104, no. 8, pp. 2269–2271, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. L. Zhang, Z. Qian, Z. Cai et al., “Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo,” American Journal of Hematology, vol. 84, no. 9, pp. 553–559, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. N. H. Fowler MP, L. Kwak, F. Hagemeister et al., “Lenalidomide and rituximab for untreated indolent non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 27, 15s, 2009, Abstract no. 8548. View at Google Scholar
  75. M. Veliz SR, J. E. Lancet, R. S. Komrokji et al., “Phase II study of lenalidomide in combination with rituximab for patients with CD5+/CD20+ hematologic malignancies who relapse or progress after rituximab: interim analysis,” Blood, vol. 114, article 2376, 2009. View at Google Scholar
  76. J. Du, H. Yang, Y. Guo, and J. Ding, “Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20,” Molecular Immunology, vol. 46, no. 11-12, pp. 2419–2423, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. W. G. Wierda, S. Padmanabhan, G. W. Chan, I. V. Gupta, S. Lisby, and A. Österborg, “Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study,” Blood, vol. 118, no. 19, pp. 5126–5129, 2011. View at Publisher · View at Google Scholar · View at Scopus
  78. E. Mössner, P. Brünker, S. Moser et al., “Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity,” Blood, vol. 115, no. 22, pp. 4393–4402, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. T. Robak, “GA-101, a third-generation, humanized and glyco-engineered anti-CD20 mAb for the treatment of B-cell lymphoid malignancies,” Current Opinion in Investigational Drugs, vol. 10, no. 6, pp. 588–596, 2009. View at Google Scholar · View at Scopus
  80. L. Bologna, E. Gotti, M. Manganini et al., “Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab,” The Journal of Immunology, vol. 186, no. 6, pp. 3762–3769, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. F. C. G. Morschhauser, T. Lamy, N. Milpied et al., “Phase I study of RO5072759 (GA101) in relapsed /refractory CLL,” in ASH Ann Meeting Abstract, vol. 114, 2009, Abstract no. 364.
  82. L. H. Sehn AS, D. A. Steward, J. Mangel, P. Pisa, J. Kothari, and M. Crump, “A Phase I study of GA101 (RO5072759) monotherapy followed by maintenance in patients with multiple relapsed/refractory CD20+ malignant disease,” in ASH Ann Meeting Abstract, vol. 114, 2009, Abstract no. 385.
  83. X. Badoux, O. 'Brien SM, W. G. Wierda et al., “Combination of ofatumumab and lenalidomide in patients with relapsed chronic lymphocytic leukemia: initial results of a phase II trial,” Blood (ASH Annual Meeting Abstracts), vol. 116, 2010, Abstract no. 2464. View at Google Scholar
  84. S. Lonial, R. Vij, J. L. Harousseau et al., “Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma,” Journal of Clinical Oncology, vol. 30, no. 16, pp. 1953–1959, 2012. View at Google Scholar
  85. K. Staveley-O'Carroll, E. Sotomayor, J. Montgomery et al., “Induction of antigen-specific T cell anergy: an early event in the course of tumor progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 3, pp. 1178–1183, 1998. View at Publisher · View at Google Scholar · View at Scopus
  86. P. Horna and E. M. Sotomayor, “Cellular and molecular mechanisms of tumor-induced T-cell tolerance,” Current Cancer Drug Targets, vol. 7, no. 1, pp. 41–53, 2007. View at Publisher · View at Google Scholar · View at Scopus